Real World Retina: Surgical Advances and Enhancements That Reduce the Burden of Treatment in Retinal Vascular Diseases

Author(s)/Faculty: Arshad M. Khanani, MD, MA, FASRS; John W. Kitchens, MD; Dante J. Pieramici, MD
Release Date: 8/12/2022Expiration Date: 8/11/2023
Credit Type: CMENumber of Credits: 1
Content Type: LectureProvider:
Intravitreal anti-vascular endothelial growth factor (VEGF) based treatment protocols for the management of retinal vascular diseases has provided significant visual and anatomical improvements, but treatment burden and loss of patient adherence due to dosing schedules often result in suboptimal outcomes. To address these unmet needs, unique delivery systems have been developed that reduce the need for frequent dosing of therapy beyond those utilized in current treatment protocols. Ongoing clinical studies are evaluating gene therapy to reduce treatment burden, while the FDA-approved Port Delivery System (PDS) with ranibizumab has demonstrated maintenance of visual acuity gains with extended treatment intervals out to 6 months. To achieve optimal efficacy and safety outcomes with these new extended treatment modalities, at the initiation of their use, unique surgical approaches must be utilized. In this CME activity, experts in the field will discuss how novel surgical advances can enhance outcomes while reducing treatment burden, review key procedural steps and surgical techniques pertaining to their use, and evaluate processes and procedures that can reduce complications from surgeries to optimize outcomes in patients with retinal vascular diseases.